Duration of Provera (Medroxyprogesterone Acetate) Use

Injectable DMPA (Depo-Provera)

• The American College of Obstetricians and Gynecologists does not recommend restricting depot medroxyprogesterone acetate (DMPA/Depo-Provera) to 2 years, as the benefits of preventing unwanted pregnancy generally outweigh the risks of bone density loss 1, 2
• No time limit exists for DMPA use, despite the FDA black box warning about bone mineral density (BMD) loss issued in 2004 2
• The ACOG explicitly states that use should not be limited to 2 years because subsequent research has demonstrated substantial recovery of BMD after discontinuation 1, 2
• Routine bone density monitoring is not recommended after 2 years of use 2
• DMPA should be administered every 3 months (13 weeks), with injections allowed up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection 1
• Both provider-administered and self-administered subcutaneous formulations are acceptable options 1
• For patients continuing DMPA beyond 2 years, counsel about skeletal health measures, including daily calcium intake of 1,300 mg 1, 2
• For patients continuing DMPA beyond 2 years, counsel about skeletal health measures, including daily vitamin D intake of 600 IU 1, 2
• For patients continuing DMPA beyond 2 years, counsel about skeletal health measures, including regular weight-bearing exercise 1, 2
• For patients continuing DMPA beyond 2 years, counsel about skeletal health measures, including smoking cessation 1, 2
• Evaluate patients for other osteoporosis risk factors when considering long-term use 2
• For patients with pre-existing osteoporosis risk factors, alternative contraceptive methods may be preferable 2
• Return to fertility may be delayed 9-18 months after discontinuation 1, 2

Oral Medroxyprogesterone Acetate

• Progestin-only pills require strict daily adherence and have higher failure rates than DMPA 3
• No specific duration limits are established in guidelines for oral progestin-only contraceptive use 3
• Continuous progestin-based therapy (including medroxyprogesterone) may be used in highly selected patients with stage IA, grade 1 endometrioid adenocarcinoma who desire fertility preservation 4
• Close monitoring with endometrial sampling every 3-6 months is mandatory 4
• Hysterectomy is recommended if endometrial cancer persists after 6 months of progestin therapy 4
• This approach achieves durable complete response in approximately 50% of patients, though ultimate recurrence rates are high (35%) 4

Key Clinical Pitfalls

• Do not discontinue DMPA at 2 years based solely on duration concerns, as this increases risk of unintended pregnancy without clear benefit 1, 2
• Do not routinely order bone density scans after 2 years of DMPA use unless other osteoporosis risk factors are present 2
• Counsel patients before initiation about menstrual changes and potential side effects to improve continuation rates 2
• Weight gain at 6 months (>5% increase) is a strong predictor of future excessive weight gain with ongoing DMPA use 2

Blood Testing for Patients on Depo-Provera Injections

Pre-Initiation Requirements

• The American Academy of Pediatrics and the Centers for Disease Control and Prevention recommend that no examinations or laboratory tests are needed before initiating DMPA, although baseline weight and BMI measurement may be useful for monitoring over time 5

Monitoring During Use

• No routine blood work is recommended during ongoing DMPA use, according to the American Academy of Pediatrics and the Centers for Disease Control and Prevention 6, 5

Bone Density Monitoring

• The American College of Obstetricians and Gynecologists states that routine bone mineral density (BMD) scans are not recommended, even after prolonged use beyond 2 years 7, 6, 8
• BMD assessment may be considered if the patient has used DMPA for more than 2 years and has additional osteoporosis risk factors, such as heavy alcohol use or smoking 6, 9

Special Populations Requiring Consideration

HIV-Infected Patients

• For HIV-infected patients on DMPA, no additional routine blood testing is required specifically for contraceptive monitoring, according to the American Academy of Pediatrics 7, 8
• DMPA levels do not appear to be reduced by antiretroviral agents, and the agent is largely free of antiretroviral interactions 7, 8

Clinical Counseling Instead of Testing

• Counseling is the key intervention for DMPA users, including age-appropriate calcium supplementation (1,300 mg daily) and vitamin D supplementation (600 IU daily) 7
• Regular weight-bearing exercise, smoking cessation, and alcohol avoidance are also recommended 7
• Weight monitoring is important, as weight gain at 6 months predicts future excessive gain 6, 9

Common Pitfalls to Avoid

• Routine laboratory panels (CBC, metabolic panel, liver function tests) should not be ordered for DMPA monitoring, as this increases healthcare costs without evidence of benefit, according to the Centers for Disease Control and Prevention 5
• Routine screening for anemia is not necessary unless the patient has symptoms or risk factors unrelated to DMPA use, as DMPA reduces menstrual bleeding over time and protects against iron-deficiency anemia 5, 9
• DEXA scans should not be ordered at 2 years of use based solely on duration, as this contradicts current guidelines and may lead to unnecessary discontinuation of effective contraception 6, 7